Abound Wealth Management’s NovoCure NVCR Stock Holding History

Abound Wealth Management’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$819	Hold	54	–	–	﹤0.01%	852
2026 Q1	$589	Hold	54	–	–	﹤0.01%	1038
2025 Q4	$699	Hold	54	–	–	﹤0.01%	929
2025 Q3	$698	Hold	54	–	–	﹤0.01%	898
2025 Q2	$962	Hold	54	–	–	﹤0.01%	806
2025 Q1	$963	Hold	54	–	–	﹤0.01%	764
2024 Q4	$1.61K	Hold	54	–	–	﹤0.01%	689
2024 Q3	$845	Hold	54	–	–	﹤0.01%	796
2024 Q2	$926	Hold	54	–	–	﹤0.01%	736
2024 Q1	$845	Hold	54	–	–	﹤0.01%	793
2023 Q4	$807	Hold	54	–	–	﹤0.01%	814
2023 Q3	$873	Hold	54	–	–	﹤0.01%	725
2023 Q2	$2.24K	Hold	54	–	–	﹤0.01%	632
2023 Q1	$3.25K	Hold	54	–	–	﹤0.01%	509
2022 Q4	$3.96K	Hold	54	–	–	﹤0.01%	391
2022 Q3	$4.1K	Buy	+54	New	+$4.21K	﹤0.01%	388

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

QCM

Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return

Abound Wealth Management's NVCR Position: Q2 2026 in Review

Abound Wealth Management held its NovoCure (NVCR) position steady in Q2 2026 at 54 shares worth $819. The position accounts for ﹤0.01% of the portfolio, ranked #852.

Abound Wealth Management first reported a position in NVCR in Q3 2022 and has held it in 16 quarters since. The position peaked at $4.1K in Q3 2022. 218 funds tracked by Wall St. Rank hold NVCR as of Q2 2026.

Abound Wealth Management held 54 shares of NovoCure worth $819 as of Q2 2026.
Abound Wealth Management left its NovoCure share count unchanged in Q2 2026.
NovoCure made up ﹤0.01% of Abound Wealth Management's portfolio in Q2 2026, its #852 holding.
Abound Wealth Management first reported a position in NovoCure in Q3 2022 and has held it in 16 quarters since.
Abound Wealth Management's NovoCure position peaked at $4.1K in Q3 2022.
218 funds tracked by Wall St. Rank held NovoCure as of Q2 2026.

Based on Abound Wealth Management's 13F filing for Q2 2026, filed 10 Jul 2026.